Evaluating Optimal Treatment for Melanoma: A Network Meta-Analysis

Rastrelli, 2014, Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification [J], In Vivo, 28, 1005 Siegel, 2020, Cancer statistics, 2020 [J], CA Cancer J Clin, 70, 7, 10.3322/caac.21590 Weide, 2019, A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients [J], Cancer Immunol Immunother, 68, 1547, 10.1007/s00262-019-02383-z Hersh, 2011, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma [J], Invest New Drugs, 29, 489, 10.1007/s10637-009-9376-8 Schachter, 2017, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) [J], Lancet, 21, 1853, 10.1016/S0140-6736(17)31601-X Larkin, 2018, Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial [J], J Clin Oncol, 36, 383, 10.1200/JCO.2016.71.8023 Hodi, 2018, Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial [J], Lancet Oncol, 19, 1480, 10.1016/S1470-2045(18)30700-9 Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma [J], N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428 Al-Badr, 2016, Dacarbazine [J], Profiles Drug Subst Excip Relat Methodol, 41, 323, 10.1016/bs.podrm.2015.12.002 Dummer, 2018, Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial [J], Lancet Oncol, 19, 1315, 10.1016/S1470-2045(18)30497-2 Paolo, 2016, Cobimetinib combined with vemurafenib in advanced BRAF (V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J], Lancet Oncol, 17, 1248, 10.1016/S1470-2045(16)30122-X Robert, 2013, Selumetinib plus dacarbazine versus placebo plus dacarbazine as firstline treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study [J], Lancet Oncol, 14, 733, 10.1016/S1470-2045(13)70237-7 Hauschild, 2009, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma [J], J Clin Oncol, 27, 2823, 10.1200/JCO.2007.15.7636 Long, 2017, Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma [J], N Engl J Med, 377, 1813, 10.1056/NEJMoa1708539